Lymphatic Mapping for Melanoma: Long-term Results of Regional Nodal Sampling with Radioguided Surgery

Ramnath, Erik M.; Kamath, D P Shrinath; Brobeil, A; Stall, A.; Kamath, Vidyulata; Cruse, C. Wayne; Glass, Frank; Messina, Jane L.; Fenske, N; Berman, Claudia G.; Ross, Merrick I.; Cantor, Alan; Cuthbertson, David; Reintgen, Douglas S.

doi:10.1177/107327489700400601

Cited by 23 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly enough, patients with involved satellite nodes presented distant metastatic spread (distant nodes or visceral metastases), while those with negative satellite nodes had only locoregional involvement (dermal in-transit or same-basin metastases). These observations confirm a series of other reports [6,11,12,[29][30][31][32].…”

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Gamma-Probe-Directed Lymphatic Mapping and Sentinel Lymphadenectomy in Primary Cutaneous Melanoma

et al. 2002

View full text Add to dashboard Cite

Background: Radiotracer and blue-dye lymphatic mapping is a recommended combined method to guide sentinel lymphadenectomy and full regional lymph node dissection in selected patients with cutaneous melanoma. Objective: To evaluate the diagnostic accuracy and the prognostic value of gamma-probe-directed lymphatic mapping in cutaneous melanomas. Methods: Sixty-five stage I and II melanoma patients underwent gamma-probe-directed lymphatic mapping. Sentinel lymph nodes were studied by both conventional and immunohistochemical stainings. The median follow-up was 11 months. Results: Sensitivities of preoperative and intraoperative sentinel lymph node detection were 100 and 98%, respectively. Only 1 failure of detection and 1 missed same-basin metastasis were experienced in the axillary and cervical areas, respectively. Eleven patients (16.9%) had sentinel node metastases leading to adjuvant therapy. Conclusion: Gamma-probe-directed lymphatic mapping is useful for staging melanoma. However, in the expectation of a more specific identification of the sentinel lymph node, the standard protocol remains recommended for exploring the axillary and cervical areas. The histological examination supported in some cases by immunohistochemistry remains mandatory in all cases.

show abstract

Section: Discussionsupporting

confidence: 82%

“…This patient was upstaged to stage IV after detecting lung metastases by computed tomography. highlighted the value of sentinel node examination in predicting the patient outcome [11][12][13]. This is particularly true for patients with AJCC stage I or II melanoma who might benefit from high-dose systemic interferon · 2b [6,8].…”

Section: Discussionmentioning

confidence: 99%

Gamma-Probe-Directed Lymphatic Mapping and Sentinel Lymphadenectomy in Primary Cutaneous Melanoma

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Literature data indicates that the percentage of patients with sN metastases varies from 11.6 up to 24% [10][11][12][13][14][15][16]. The positivity is directly related to the tumor thickness: 4.8% in melanoma less than 1.5 mm; 19.2% in melanoma between 1.5 and 4 mm; and 34.4% in melanoma over 4 mm, as reported by Ross [12].…”

Section: Discussionmentioning

confidence: 57%

Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review

Gipponi¹,

Somma²,

Peressini³

et al. 2004

Journal of Surgical Oncology

View full text Add to dashboard Cite

Sentinel node lymphadenectomy can be better accomplished when both procedures (lymphatic mapping with Patent Blue-V and RGS) are used because the two methods look quite complementary. In fact, the use of the radiocolloid mapping allows to detect a hot spot in the regional basin prior to making the skin incision in order to perform a minimal invasive access, and it may also more accurately differentiate the true sN from a secondary echelon node (non-sN). The use of frozen section examination should be restricted to patients with pT(3)-pT(4) primary melanoma, due to the higher sensitivity and benefit in terms of avoiding a two-stage operative procedure.

show abstract

“…ütün çal şmalarda prognozu değerlendirmek için ekstremiteler, baş-boyun e gö de olarak üç k sma ayr larak incelenmiştir. Ramnath e arkadaşlar n n çal şmas nda 461 olgunun %43,8'inde gö de, %39,3'ünde ekstremitelerde, %16,9'u baş boyun bölgesinde olarak rapor edilmiştir (14).…”

Section: Discussionunclassified

“…Malign melanomda en iyi tan mlanm ş prognostik faktörlerden birisi breslow kal nl ğ olup breslow kal nl ğ artt kça sağkal m k salmaktad r. Ramnath e arkadaşlar 480 hastal k çal şmas nda breslow kal nl ğ ile sağkal m aras nda ters ilişki saptam şlard r (14). Le i e arkadaşlar 1229 hasta içeren çal şmas nda breslow kal nl ğ artt kça sağkal m n k sald ğ n saptam şlard r (16).…”

Section: Discussionunclassified

Clinicopathological Analysis of Patients with Malign Melanoma

Aydın¹,

Ünal²,

Somali³

et al. 2015

Acta Oncol Tur.

View full text Add to dashboard Cite

1 okuz ylül Üni ersitesi T p akültesi ç Hastal klar Ana ilim al , zmir, Türkiye. 2 zmir ozyaka ğitim Ve Araşt rma Hastanesi T bbi Onkoloji ölümü, zmir, Türkiye. 3 okuz ylül Üni ersitesi T p akültesi ç Hastal klar Ana ilim al ,t bbi Onkoloji ilim al , zmir, Türkiye. 4 zmir Üni ersitesi T p akültesi ç Hastal klar Ana ilim al ,t bbi Onkoloji ilim al , zmir, Türkiye. ÖZET GİRİŞ ve AMAÇ: u çal şmada Malign Melanom tan l hastalar n Klinikopatolojik özelliklerini incelemeyi amaçlad k. YÖNTEM ve GEREÇLER: u çal şmada okuz ylül Üni ersitesi Hastanesi T bbi Onkoloji bölümünde 1991-2011 Y llar aras nda takip edilen malign melanom tan l 166 hasta retrospektif olarak değerlendirilmiştir. BULGULAR: Hastalardan 87'si erkek, 79'u kad nd r. Tüm hastalar n ortanca yaş 52 (21-81) dir. n s k extremite bölgesinde malign melanom görülürken daha az s kl kta baş boyun e gö dede gözlenmiştir. Primer tümör bölgesi ile breslow kal nl ğ aras nda istatistiksel bir anlaml l k saptanmam şt r(p=0.109). Ancak breslow kal nl ğ ile sağ kal m aras nda istatistiksel bir fark bulunmuştur. reslow kal nl ğ 0-2 mm aras nda olanlar n ortalama sağkal m 125,6 ay(99-151), 2-4 mm aras nda olanlar n ortalama sağkal m 121,2 ay(92-151), 4 mm ve üstünde olanlar n ortalama sağkal m 89 ay(68-111) olarak saptanm şt r e aradaki fark istatistiksel olarak anlaml saptanm şt r(p=0,012). Tüm hastalar n 1 y ll k sağkal m oran %96, iki y ll k sağkal m oran %92.1 e 5 y ll k sağkal m oran %82.7 saptan rken; ortalama sağkal m süresi 89,74±6,9 ay olarak saptanm şt r. Kad n cinsiyette ortalama sağkal m 108.8 ay, erkeklerde ortalama sağkal m 72.7 ay saptanm ş olup aradaki fark istatistiksel olarak anlaml bulunmuştur(P=0,001). Melanomun primer yerleşim yerine göre sağkal mlar s ras yla baş-boyun yerleşiminde 69.6 ay, gö de 114.1 ay, extremite yerleşiminde 82.0 ay olup aradaki fark istatistiksel olarak anlaml saptanmam şt r(P=0,32). TARTIŞMA ve SONUÇ: Malign melanom en kötü seyirli deri tümörü olup prognozu etkileyen faktörler birden fazlad r. u çal şmada en önemli prognostik faktörler breslow kal nl ğ , primer tümör yerleşim bölgesi e cinsiyet olarak saptanm şt r. Anahtar Kelimeler: Malign melanoma, prognoz. ABSTRACT INTRODUCTION:Our aim in this study is to analyse patients with malign melanoma clinicopathologically. METHODS: In this study, 166 malign melanoma patients that followed by Dokuz Eylul University Hospital Medical Oncology Clinic in years between 1996 and 2011 were evaluated retrospectively. RESULTS: 87 of patients is male, 79 is female. The median age is 52 (21-81). The most common site for malign melanoma is extremity; head, neck and body are less commonly involved. There is no statistically significant difference between primary tumor site and breslow thickness (p=0.109). Breslow thickness and survival are related statistically significant. Average survival time for Breslow thickness between 0 and 2mm is 125,6 months (99-151), 2 and 4 mm is 121,2 months (92-151) and over 4mm is 89 months (68-111) and difference between groups are statistically significant (p=0,012)...

show abstract

Lymphatic Mapping for Melanoma: Long-term Results of Regional Nodal Sampling with Radioguided Surgery

Cited by 23 publications

References 27 publications

Gamma-Probe-Directed Lymphatic Mapping and Sentinel Lymphadenectomy in Primary Cutaneous Melanoma

Gamma-Probe-Directed Lymphatic Mapping and Sentinel Lymphadenectomy in Primary Cutaneous Melanoma

Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review

Clinicopathological Analysis of Patients with Malign Melanoma

Contact Info

Product

Resources

About